Prospective study of perinatal outcome in pregnancies with primary antiphospholipid syndrome

Aleksandar Ćetković; Biljana Kastratović; Ivana Novaković

doi:10.2298/3504

Aleksandar Ćetković Clinic of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade
Biljana Kastratović Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ivana Novaković Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/3504

Keywords: antiphospholipid syndrome, pregnancy outcome, aspirin, heparin, low-molecular-weight,

Abstract

Background/Aim. Pregnancies complicated with antiphospholipd syndrome are associated with the increased perinatal mortality and morbidity. The aim of this study was to assess perinatal outcome in pregnancies with primary antiphospholipd syndrome. Methods. This prospective study evaluated perinatal outcome in 25 pregnant women with antiphospholipid syndrome. After establishing vital pregnancy all the patients were treated with low-molecular-weight heparin and aspirin. The perinatal outcome was measured by rates of miscarriages, preterm deliveries, live births and neonatal complications. Results. Of the 25 pregnancies, 20 (80%) resulted in live birth, 3 (12%) in spontaneous abortion and 2 (8%) were stillbirths. The mean gestational age at delivery was 37.2 ± 1.0 weeks, mean neonatal birth weight was 2,930.4 ± 428.0 g. Prematurity occurs in 4 (20%) live births, and there were 4 (20%) intrauterine growth restriction with mean birth weight 2,060 ± 210.6 g. Neonatal complications were present in 6 (30%) newborns. Adverse perinatal outcome was significantly associated with anticardiolipin IgG antibodies (p < 0.01) and development of hypertension during pregnancy (p < 0.01). Conclusion. Despite a high incidence of adverse perinatal outcomes in pregnancies with primary antiphospholipid syndrome, early treatment with aspirin and low-molecular-weight heparin, combined with meticulous fetomaternal monitoring could be associated with a relatively high probability of favorable perinatal outcome.

References

Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346(10): 752−63.

Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierengeli S, et al. Antiphospholipid syndrome clinical research task force report. Lupus 2011; 20(2): 219−24.

Xiao J, Xiong J, Zhu F, He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syn-drome. Exp Therap Med 2013; 5(1): 287−91.

Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, et al. Treatment of pregnant patients with antiphospholipid syn-drome. Lupus 2003; 12(7): 524−9.

Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99(1): 135−44.

Branch DW, Kamashta MA. Antiphospholipid syndrome: obste-tric diagnosis, management and controversies. Obstet Gy-necol 2003; 101(6): 1333−44.

Tadej A. Antiphospholipid antibody syndrome. In: Elzouki AY, Harfi HA, Nazer H, William OH, Stapleton FB, Whitley RJ, editors. Textbook of clinical pediatrics. 2nd ed. Berlin: Sprin-ger; 2012. p. 1641−8.

Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182(1 Pt 1): 122−7.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4(2): 295−306.

Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171−96.

Costa SL, Proctor L, Dodd JM, Toal M, Okun N, Johnson JA, et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta 2008; 29(12): 1034−40.

Durutović-Gligorović S. Antropometric normative for newborns Belgrade: Faculty of Medicine University of Belgrade; 2000. (Serbian)

Ruffati A, Tonnelo M, Cavazzana A, Bagatella P, Pengo V. Labora-tory classification and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123(3): 482−7.

Serrano F, Nogueira I, Borges A, Branco J. Primary antiphopsholi-pid syndrome: pregnancy outcome in a portugese population. Acta Reumatol Port 2009; 34(3): 492−7.

Lockshin MD. Pregnancy and Antiphospholipid Syndrome. Am J Reprod Immunol 2012. doi: 10.1111/aji.12071. (In Press)

Di Prima F, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E, et al. Antiphospholipid syndrome during pregnancy: the state of art. J Prenatal Med 2011; 5(2): 41−53.